Pharmacogenomics in Alzheimer's disease

Area of Science:

• Genetics and Genomics
• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease (AD) is a complex neurological disorder with genetic and environmental influences.
• Current understanding of AD genetics is incomplete, suggesting roles for epigenetics and environmental factors.
• Genomics is advancing the study of AD's genetic epidemiology, risk factors, and pathogenic mechanisms.

Purpose of the Study:

• To explore the role of genomics and pharmacogenomics in understanding Alzheimer's disease.
• To investigate genotype-specific responses to multifactorial therapy in AD patients.
• To highlight the potential of functional genomics and pharmacogenomics in drug development and clinical trials for AD.

Main Methods:

• Analysis of genetic associations using bigenic, trigenic, and polygenic models.
• Application of pharmacogenomic models to study genotype-specific drug responses.
• Evaluation of multifactorial therapy outcomes based on APOE genotype and other gene variants.

Main Results:

• Therapeutic response to AD drugs is genotype-specific, particularly influenced by APOE variants.
• A multifactorial therapy showed positive results in 60% of patients, with varying efficacy across APOE genotypes.
• Bigenic and trigenic models differentiated the impact of PS1 and PS2 variants on treatment response.

Conclusions:

• Functional genomics and pharmacogenomics are crucial for advancing AD molecular diagnosis and clinical trials.
• Optimizing drug development and therapeutics in AD requires integrating pharmacogenomic insights for increased efficacy and safety.
• Genomic approaches offer a pathway to personalized medicine for Alzheimer's disease, reducing side effects and costs.